US Stock Insider Trading | Clene Discloses 1 Insider Transaction on February 5

K-LinePoet · 2026-02-25T03:56:08+00:00

On February 5, 2026, Clene (CLNN) disclosed an insider trading transaction. Shareholder Ugwumba Chidozie, holding more than 10% of shares, sold 5,559 shares on February 3, 2026.【Recent Insider Trading】| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share/USD | Total Amount/USD || --- | --- | --- | --- | --- | --- | --- | --- || February 5, 2026 | Shareholder with over 10% | Ugwumba Chidozie | February 3, 2026 | Sell | 5,559 | 4.10 | $22,800 || 20

K-LinePoet

2026-02-25 03:56:08

On February 5, 2026, Clene (CLNN) disclosed a company insider trading transaction. Shareholder Ugwumba Chidozie, holding more than 10% of shares, sold 5,559 shares on February 3, 2026.

[Recent Insider Trading]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 5, 2026	Shareholder >10%	Ugwumba Chidozie	February 3, 2026	Sell	5,559	4.10	$22,800
February 2, 2026	Shareholder >10%	Ugwumba Chidozie	January 29, 2026	Sell	15,300	4.32	$66,000
February 2, 2026	Shareholder >10%	Ugwumba Chidozie	February 2, 2026	Sell	3,800	4.04	$15,400
February 2, 2026	Shareholder >10%	Ugwumba Chidozie	January 30, 2026	Sell	5,686	4.13	$23,500
January 28, 2026	Shareholder >10%	Ugwumba Chidozie	January 26, 2026	Sell	6,418	5.02	$32,200
January 28, 2026	Shareholder >10%	Ugwumba Chidozie	January 27, 2026	Sell	4,139	5.08	$21,000
January 28, 2026	Shareholder >10%	Ugwumba Chidozie	January 28, 2026	Sell	8,717	4.91	$43,000
January 23, 2026	Shareholder >10%	Ugwumba Chidozie	January 22, 2026	Sell	12,700	5.32	$67,400
January 23, 2026	Shareholder >10%	Ugwumba Chidozie	January 23, 2026	Sell	5,556	5.27	$29,300
January 21, 2026	Shareholder >10%	Ugwumba Chidozie	January 21, 2026	Sell	12,100	5.05	$61,200

[Company Profile]

Clene Inc. was founded on November 13, 2017. Clene is a clinical-stage biopharmaceutical company dedicated to developing unique therapies for neurodegenerative diseases. Clene has invented a novel nanotechnology drug platform for developing new oral neurotherapeutics. The company is also advancing a zinc and silver ion aqueous solution for antiviral and antibacterial applications into clinical trials.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.